Galectin Therapeutics (GALT) Payables (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Payables of $3.1 million for Q1 2026, down 54.36% year-over-year from $6.8 million in Q1 2025, and down 5.65% quarter-over-quarter from $3.3 million in Q4 2025.
Galectin Therapeutics (GALT) Payables (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- In Q1 2026, Payables fell 54.36% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 54.36% YoY), while the FY2025 annual figure was $3.3 million, down 45.66% from the prior year.
- Payables for Q1 2026 stood at $3.1 million, down from $3.3 million in the prior quarter.
- The five-year high for Payables was $9.1 million in Q3 2025, with the low at $1.9 million in Q1 2022.
- The 5-year median for Payables is $3.3 million (2025), against an average of $4.1 million.
- The sharpest annual moves came in 2022 and 2026: Payables soared 398.95% in 2022, then tumbled 54.36% in 2026.
- Galectin Therapeutics' Payables stood at $4.0 million in 2022, then surged by 64.24% to $6.5 million in 2023, then dropped by 6.25% to $6.1 million in 2024, then slumped by 45.66% to $3.3 million in 2025, then retreated by 5.65% to $3.1 million in 2026.
- Business Quant data shows GALT's Payables at $3.1 million in Q1 2026, $3.3 million in Q4 2025, and $9.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.12 Mn |
| Dec 31, 2025 | 3.31 Mn |
| Sep 30, 2025 | 9.13 Mn |
| Jun 30, 2025 | 5.93 Mn |
| Mar 31, 2025 | 6.84 Mn |
| Dec 31, 2024 | 6.09 Mn |
| Sep 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 6.49 Mn |
| Sep 30, 2023 | 2.68 Mn |
| Jun 30, 2023 | 2.04 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 3.95 Mn |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 3.03 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Sep 30, 2021 | 1.92 Mn |
| Jun 30, 2021 | 989,000.00 |